Chronic Kidney Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Kidney Disease stocks.

Chronic Kidney Disease Stocks Recent News

Date Stock Title
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Jul 2 ARDX Ardelyx stock tumbles 20% on CMS payment update
Jul 2 AZN AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
Jul 2 OPK NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner
Jul 2 ARDX To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
Jul 2 SNY Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 2 AZN EMA fast-tracks review of AstraZeneca’s sipavibart to stop Covid
Jul 1 AZN AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 AZN AstraZeneca COVID prevention antibody gets EU fast-track review
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
Chronic Kidney Disease

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months or years. Early on there are typically no symptoms. Later, leg swelling, feeling tired, vomiting, loss of appetite, or confusion may develop. Complications may include heart disease, high blood pressure, bone disease, or anemia.Causes of chronic kidney disease include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Risk factors include a family history of the condition. Diagnosis is generally by blood tests to measure the glomerular filtration rate and urine tests to measure albumin. Further tests such as an ultrasound or kidney biopsy may be done to determine the underlying cause. A number of different classification systems exist.Screening at-risk people is recommended. Initial treatments may include medications to manage blood pressure, blood sugar, and lower cholesterol. NSAIDs should be avoided. Other recommended measures include staying active and certain dietary changes. Severe disease may require hemodialysis, peritoneal dialysis, or a kidney transplant. Treatments for anemia and bone disease may also be required.Chronic kidney disease affected 753 million people globally in 2016, including 417 million females and 336 million males. In 2015 it resulted in 1.2 million deaths, up from 409,000 in 1990. The causes that contribute to the greatest number of deaths are high blood pressure at 550,000, followed by diabetes at 418,000, and glomerulonephritis at 238,000.

Browse All Tags